08:02 AM EST, 02/03/2025 (MT Newswires) -- BioNTech (BNTX) said Monday it has completed its acquisition of Biotheus for $800 million, primarily in cash, and gained full global rights to BNT327 and Biotheus' portfolio of antibody candidates.

The consideration also includes up to $150 million performance-based payments if certain goals are met, BioNTech said.

Biotheus will now operate as an indirect Chinese subsidiary, adding a regional research center and advanced biologics production facility to BioNTech's operations, according to BioNTech.

The acquisition is part of BioNTech's plan to commercialize BNT327 as a pan-tumor technology platform for combination therapies, the company added.

BioNTech shares were down more than 2% in recent premarket activity.